Luneau Technology have merged with Optovue Global Inc. ‘creating a complete offering for eyecare physicians and transforming access to visual health for patients.’ Dr Marc Abitbol, CEO of Luneau Technology said of the merger “… our expertise is very complementary. What we’re doing now is uniting these two technologies to bring smarter, better, higher-precision solutions to the market.” Meanwhile, Peter Wyles, CEO of Optovue said “We are thrilled to work together toward our common vision, while at the same time, significantly optimizing the customer experience”.

Genentech have announced that the FDA has approved Susvimo 100 mg/mL for intravitreal use, via ocular implant, to treat people with wet age-related macular degeneration. This is the first and only FDA-approved treatment for wet AMD that offers as few as two treatments per year. “Susvimo represents a major advancement in the treatment of retinal disease and is an important new option for patients with wet AMD,” Carl Regillo, MD, Chief of Retina Service at Wills Eye Hospital.

WE HAVE RAISED £1,581.00 IN OUR WALK FOR WORLD SIGHT DAY EVENT 👁 (158% of our fundraising target)

Last Thursday the 14th October, in aid of World Sight Day, the Vision Executives team, as well as, friends and family endeavoured to climb the Yorkshire Three Peaks in less than 12 hours. We completed the 25 mile 5200ft challenge with just 15 minutes to go and therefore collected the final funds from our sponsors earlier this week. To put this in perspective, the final amount of £1581.00 will pay for sight saving surgeries in some of the remote areas around the world and be used to train new opticians, optometrists and opthalmologits ensuring a sustainable future for regions with little or no access to eyecare services.

The funds will be divided equally between three amazing and worthwhile charities: Sight For All, Himalayan Cataract Project and ANDEAN MEDICAL MISSION.

Vision Executives would like to thank everyone who contributed to our article (link in comments), donated and participated for your support. Also big thanks to Aleksandra Jones at the The Ophthalmologist for sharing with their network.

Bausch + Lomb + Lamb have announced their topline results from their first Phase 3 trial of NOV03 – a first-in-class eye drop with the novel mechanism of action to treat the signs and symptoms of dry eye disease linked to Meibomian Gland Dysfunction.

Dry eye disease is a common ocular problem, affecting at least 16 million people in America, meanwhile Meibomian Gland Dysfunction accounts for 86% of dry eyes. The Phase 3 trial is showing statistically significant improvements in both the signs and symptoms of dry eye disease.

“The rapid onset of action and statistical significance demonstrated in this trial is impressive. It also gets us a step closer to bringing forward this potential first-in-class treatment option, which could be a promising development for millions of patients.” Joseph Papa, chairman and CEO, Bausch Health.

Ref: https://www.novaliq.com/press-releases/2021/04/13/partner-bausch-lomb-announces-statistically-significant-topline-results-from-the-first-phase-3-trial-of-nov03/

Johnson and Johnson Vision showcased their new Veritas Vision System and a range of clinical data relating to their products at the ESCRS. Veritas Vision System is a phaco system designed to address three critical areas: patient system, surgeon efficiency and comfort. Johnson and Johnson Vision have also presented several other products at ESCRS, including Tecnis Synergy IOL, Tecnis Eyhance IOL and Tecnis Toric II IOL. “The Veritas Vision System is designed to give better fluidics and increased chamber stability, and has had excellent feedback from the clinical community.” Warren Foust, Worldwide President, Surgical at Johnson & Johnson Vision.

Plasmapp has showcased the world’s fastest sterilizer, STERLINK – a novel plasma sterilizer for medical devices using STERPACK technology which enables the fastest sterilization cycle time at low temperatures. STERLINK’s safety and reliability as medical equipment is proven by FDA approval in 14 countries. It is also free from toxic EO gas, making it eco-friendly and harmless.

VSY Biotechnologies launched its first trifocal IOL at the ESCRS Symposium. With the tri-focal lens, VSY Biotechnologies are introducing their concept of Golden Ratio in IOL Technology™ with AcrivaUD Trinova Pro C Pupil Adaptive™ for cataract and Refractive Lens Exchange patients to provide the highest level of visual quality in various lighting.

Lumenis presents its first FDA-approved IPL OptiLight to treat dry eye disease due to meibomian gland dysfunction and provide a precise and comfortable dry eye procedure for patients. OptiLight elevates dry eye management with Lumenis’ patented Optimal Pulse Technology™ and user-centred design.

Ref: https://eyewire.news/news/johnson-johnson-vision-showcases-new-veritas-vision-system-and-presents-latest-clinical-data-at-escrs-2021 https://ophthalmologybreakingnews.com/plasmapp-showcases-the-worlds-fastest-sterilizer-sterlinktm-at-escrs-2021- https://ophthalmologybreakingnews.com/vsy-biotechnology-readies-for-the-launch-of-first-trifocal-iol-at-escrs-satellite-symposium- https://ophthalmologybreakingnews.com/escrs--lumenis-presents-the-first-and-only-fda-approved-ipl-optilight-to-treat-dry-eye-disease-

Advernum Biotechnologies have announced their promising long-term data from the OPTIC clinical trial of ADVM-022 single – an intravitreal injection for gene therapy in patients with wet age-related macular degeneration (AMD). The data is reflective of patients who have been followed for up to 2 years in order to determine the efficacy of the treatment. “We are very pleased to report that both the promising safety profile and durability of treatment effect continue to be maintained in this patient population,” Laurent Fischer, MD, president and chief executive officer at Adverum Biotechnologies.

Gyroscope Therapeutics have presented their positive interim Phase 1/2 data for investigational gene therapy. The clinical trial focuses on people with geographic atrophy and age-related macular degeneration (AMD). The safety data from 28 patients showed it to be well tolerated with no adverse events. Biomarker data from 13 patients, ranging from 7 months to 2 years, demonstrated sustained increases in vitreous complement factor I levels. “It’s an exciting time in complement research, and we believe a one-time gene therapy has the potential to be a long-term solution for people with geographic atrophy” Nadia Waheed, MD, MPH, Chief Medical Officer, Gyroscope Therapeutics.

REF: https://eyewire.news/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients https://eyewire.news/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients